PC
CNCE

Paulson & Co’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Paulson & Co’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-70,229
Closed -$1.2M – 119
2017
Q1 		$1.2M Buy
+70,229
New +$842K 0.02% 89

Other funds holding CNCE

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM

Paulson & Co's CNCE Position: Q2 2017 in Review

Paulson & Co sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2017, closing a stake of 70,229 shares — an estimated $1.2M sold.

Paulson & Co first reported a position in CNCE in Q1 2017 and held it in 1 quarter. The position peaked at $1.2M in Q1 2017. 79 funds tracked by Wall St. Rank hold CNCE as of Q2 2017.

  • Paulson & Co reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Paulson & Co sold 70,229 Concert Pharmaceuticals, Inc. shares in Q2 2017, an estimated $1.2M.
  • Paulson & Co first reported a position in Concert Pharmaceuticals, Inc. in Q1 2017 and held it in 1 quarter.
  • Paulson & Co's Concert Pharmaceuticals, Inc. position peaked at $1.2M in Q1 2017.
  • 79 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2017.

Based on Paulson & Co's 13F filing for Q2 2017, filed 14 Aug 2017.